A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
U.K.-based biotechnology company F2G has raised $100 million to complete late-stage testing of a new kind of antifungal treatment and bring it back to U.S. regulators’ desks after they rejected it ...